A simple method to evaluate reactivity of acylglucuronides optimized for early stage drug discovery

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 9, 2013, Pages 1509-1513

  Jinno, Norimasa ^a,b   Ohashi, Shigeki ^a   Tagashira, Mizuka ^a   Kohira, Terutomo ^a   Yamada, Shizuo ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Acylglucuronide; Chemical stability; Early drug discovery

Indexed keywords

ACYLGLUCURONIDE; CHEMICAL COMPOUND; DICLOFENAC; FLUFENAMIC ACID; FUROSEMIDE; GEMFIBROZIL; IBUPROFEN; NAPROXEN; POTASSIUM DIHYDROGEN PHOSPHATE; PROBENECID; TELMISARTAN; TOLMETIN; UNCLASSIFIED DRUG; ZOMEPIRAC;

ARTICLE; BIOSYNTHESIS; CHEMICAL REACTION; CONTROLLED STUDY; DEGRADATION; DRUG HALF LIFE; HUMAN; HUMAN CELL; IDIOSYNCRATIC DRUG TOXICITY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; TOXICITY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DISCOVERY; GLUCURONIDES; HALF-LIFE; HUMANS; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHOSPHATES; POTASSIUM COMPOUNDS; TANDEM MASS SPECTROMETRY;

EID: 84884609633     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00329     Document Type: Article

References (13)

1. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev., 24, 5-47 (1992).
2. Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos., 27, 1143-1149 (1999).
3. Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Devel., 4, 55-59 (2001).
4. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 29, 687-710 (2007).
5. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET. Predictability of the covalent binding of acidic drugs in man. Life Sci., 53, PL141-PL146 (1993).
6. Boelsterli UA. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab., 3, 439-450 (2002).
7. Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T. Development of an in vitro screening model for the biosynthesis of acylglucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab. Dispos., 30, 404-413 (2002).
8. Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, Okazaki O. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab. Dispos., 38, 1857-1864 (2010).
9. Chen Z, Holt TG, Pivnichny JV, Leung K. A simple in vitro model to study the stability of acylglucuronides. J. Pharmacol. Toxicol. Methods, 55, 91-95 (2007).
10. Bolze S, Lacombe O, Durand G, Chaimbault P, Massière F, Gay-Feutry C, Bromet N, Hulot T. Standardization of a LC/MS/MS method for the determination of acyl glucuronides and their isomers. Curr. Sep., 20, 55-59 (2002).
11. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 17, 3-16 (2004).
12. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 37, 1970-1977 (2009).
13. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos., 37, 2383-2392 (2009).